Lung Cancer
Conditions
Interventions
Intervention group: Liposomal bupivacaine chest wall local infiltration analgesia group:Given the slow onset of liposomal bupivacaine, to ensure adequate analgesia by the end of surgery, the following
Ropivacaine group: Ropivacaine local infiltration with PCA.:Given the rapid onset of ropivacaine, intercostal injection was performed prior to chest closure. A 22G scalp needle (with infusion line) wa
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Patients scheduled to undergo SP-VATS lung resection, including lobectomy, segmentectomy, or wedge resection; 2. Require postoperative analgesia via intercostal nerve block alone or in combination with patient-controlled analgesia; 3. Aged 18–70 years; 4. American Society of Anesthesiologists (ASA) physical status classification I–III; 5. Patients and their families have been informed and have voluntarily provided written informed consent to participate in this study; 6. No severe impairment of cardiac, hepatic, or renal function.
Exclusion criteria
Exclusion criteria: 1. History of previous thoracic surgery. 2. Severe pleural adhesions. 3. Infection at the puncture site. 4. Requirement for bilateral surgery during the same anesthetic period. 5. Conversion to multiport video-assisted thoracoscopic surgery or thoracotomy intraoperatively. 6. Failure of chest wall local infiltration analgesia or PCA catheter placement. 7. Pregnancy or lactation. 8. History of allergy to local anesthetics or hypersensitivity to any component of the study drugs. 9. Neurological diseases, history of nerve injury, or psychiatric disorders that may interfere with pain assessment. 10. Severe cardiovascular, hepatic, or renal dysfunction that may affect drug metabolism or safety evaluation. 11. Coagulation disorders or use of anticoagulants, increasing the risk of bleeding during chest wall infiltration. 12. Pre-existing significant pain that may interfere with postoperative pain evaluation. 13. Recent use (within 1 month) of medications that may affect analgesic efficacy, such as chronic opioid users. 14. Patient or legal guardian refusal to participate or inability to cooperate with the study. 15. Any other condition considered by the investigator to potentially affect study safety or outcomes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak pain score within 24 hours postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative pain scores at various time points;Postoperative complication rate;Postoperative recovery;Compliance with PCA;Number of rescue analgesic requests and Total supplemental opioid consumption and Total supplemental NSAID consumption;Postoperative Pulmonary Complications;Clavien-Dindo Classification of Postoperative Complications;Chest Tube Duration and Complications;Quality of Recovery;Postoperative incisional chronic pain and numbness (at 1, 3, 6 months); | — |
Countries
China
Contacts
Public ContactJiandong Mei
West China Hospital, Sichuan University
Outcome results
None listed